John P Chalmers

List of Publications by Year in descending order

451 papers	41,678 citations	4370 86 h-index	2736 192 g-index
457 all docs	457 docs citations	457 times ranked	36819 citing authors

#	Article	IF	Citations
1	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2560-2572.	13.9	6,447
2	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, The, 2016, 387, 957-967.	6.3	2,464
3	Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine, 2010, 363, 1410-1418.	13.9	1,279
4	Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. New England Journal of Medicine, 2013, 368, 2355-2365.	13.9	1,269
5	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet, The, 2012, 380, 1662-1673.	6.3	984
6	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet, The, 2016, 387, 435-443.	6.3	792
7	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, The, 2010, 375, 1875-1884.	6.3	788
8	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 1813-1821.	3.0	787
9	Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Archives of Internal Medicine, 2003, 163, 1069.	4.3	780
10	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Clinical Hypertension, 2014, 16, 14-26.	1.0	768
11	Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney International, 2011, 79, 1341-1352.	2.6	759
12	Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology, The, 2008, 7, 391-399.	4.9	732
13	Effects of Different Blood Pressureâ€"Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine, 2005, 165, 1410.	4.3	710
14	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2015, 3, 514-525.	5.5	604
15	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2014, 371, 1392-1406.	13.9	520
16	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Hypertension, 2014, 32, 3-15.	0.3	498
17	Prevalence, Awareness, Treatment, and Control of Hypertension in China. Circulation, 2008, 118, 2679-2686.	1.6	467
18	Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke. Circulation, 2005, 112, 1644-1650.	1.6	422

#	Article	IF	Citations
19	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	6.3	414
20	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature Communications, 2016, 7, 10023.	5.8	412
21	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2012, 9, e1001293.	3.9	389
22	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2017, 5, 431-437.	5.5	379
23	Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. New England Journal of Medicine, 2016, 374, 2313-2323.	13.9	352
24	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia, 2014, 57, 2465-2474.	2.9	346
25	Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial. Diabetes Care, 2014, 37, 2359-2365.	4.3	284
26	Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension, 2006, 24, 1201-1208.	0.3	262
27	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 2013, 83, 517-523.	2.6	256
28	Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 883-892.	3.0	245
29	Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. Journal of Hypertension, 1991, 9, 675-694.	0.3	236
30	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care, 2009, 32, 2068-2074.	4.3	230
31	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal, 2008, 29, 2669-2680.	1.0	225
32	Effects of Early Intensive Blood Pressure-Lowering Treatment on the Growth of Hematoma and Perihematomal Edema in Acute Intracerebral Hemorrhage. Stroke, 2010, 41, 307-312.	1.0	224
33	UKPDS and the Legacy Effect. New England Journal of Medicine, 2008, 359, 1618-1620.	13.9	221
34	Effects of Blood Pressure Reduction in Mild Hypertension. Annals of Internal Medicine, 2015, 162, 184-191.	2.0	219
35	Mobile Phone Apps to Improve Medication Adherence: A Systematic Stepwise Process to Identify High-Quality Apps. JMIR MHealth and UHealth, 2016, 4, e132.	1.8	217
36	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation, 2016, 134, 1637-1650.	1.6	205

#	Article	IF	Citations
37	Hematoma growth and outcomes in intracerebral hemorrhage. Neurology, 2012, 79, 314-319.	1.5	199
38	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
39	Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurology, The, 2014, 13, 364-373.	4.9	193
40	Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal, 2009, 30, 1128-1135.	1.0	192
41	The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. PLoS Medicine, 2008, 5, e207.	3.9	189
42	The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension, 2011, 29, 4-16.	0.3	189
43	Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Circulation, 2013, 128, 1325-1334.	1.6	189
44	Effects of Perindopril-Based Lowering of Blood Pressure on Intracerebral Hemorrhage Related to Amyloid Angiopathy. Stroke, 2010, 41, 394-396.	1.0	188
45	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care, 2016, 39, 694-700.	4.3	184
46	Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet, The, 2019, 393, 877-888.	6.3	178
47	Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2010, 56, 956-965.	1.2	171
48	Statins and Intracerebral Hemorrhage. Circulation, 2011, 124, 2233-2242.	1.6	164
49	Genomewide Association Study Using a High-Density Single Nucleotide Polymorphism Array and Case-Control Design Identifies a Novel Essential Hypertension Susceptibility Locus in the Promoter Region of Endothelial NO Synthase. Hypertension, 2012, 59, 248-255.	1.3	144
50	Associations of Proinflammatory Cytokines With the Risk of Recurrent Stroke. Stroke, 2008, 39, 2226-2230.	1.0	142
51	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021, 64, 275-287.	2.9	140
52	Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ: British Medical Journal, 2010, 340, c1104-c1104.	2.4	136
53	World Health Organisationâ€“International Society of Hypertension (WHO/ISH) Hypertension Guidelines. Clinical and Experimental Hypertension, 2004, 26, 747-752.	0.5	134
54	Effects of an Angiotensin-converting Enzyme Inhibitorâ€“based Regimen on Pneumonia Risk. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1041-1045.	2.5	133

#	Article	IF	Citations
55	Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurology, The, 2019, 18, 857-864.	4.9	133
56	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
57	Prognostic Significance of Perihematomal Edema in Acute Intracerebral Hemorrhage. Stroke, 2015, 46, 1009-1013.	1.0	132
58	Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. Diabetes, 2016, 65, 803-817.	0.3	131
59	The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition. Hypertension, 2003, 42, 297-303.	1.3	129
60	Proteinuria and Stroke: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 2009, 53, 417-425.	2.1	128
61	Mortality patterns in hypertension. Journal of Hypertension, 2011, 29, S3-S7.	0.3	127
62	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 393-398.	3.1	127
63	Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke. Stroke, 2005, 36, 2143-2147.	1.0	123
64	Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis. PLoS Medicine, 2010, 7, e1000236.	3.9	122
65	eHealth Literacy: Predictors in a Population With Moderate-to-High Cardiovascular Risk. JMIR Human Factors, 2017, 4, e4.	1.0	121
66	Cardiovascular risk perception and evidenceâ€“practice gaps in Australian general practice (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	0.8	118
67	Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study. Diabetes, 2014, 63, 1115-1123.	0.3	118
68	Evidence for an excitatory amino acid pathway in the brainstem and for its involvement in cardiovascular control. Brain Research, 1989, 496, 401-407.	1.1	116
69	Management of the hypertensive patient with elevated heart rate. Journal of Hypertension, 2016, 34, 813-821.	0.3	116
70	Erectile Dysfunction Severity as a Risk Marker for Cardiovascular Disease Hospitalisation and All-Cause Mortality: A Prospective Cohort Study. PLoS Medicine, 2013, 10, e1001372.	3.9	112
71	Severe Cerebral White Matter Hyperintensities Predict Severe Cognitive Decline in Patients With Cerebrovascular Disease History. Stroke, 2009, 40, 2219-2221.	1.0	110
72	Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 2012, 60, 770-778.	2.1	110

#	Article	IF	Citations
73	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2017, 5, 718-728.	5.5	110
74	Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 312-319.	3.1	108
75	Severe Amnesia After Hypoglycemia: Clinical, Psychometric, and Magnetic Resonance Imaging Correlations. Diabetes Care, 1991, 14, 922-925.	4.3	105
76	Acute post-stroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study. Lancet Neurology, The, 2014, 13, 374-384.	4.9	103
77	Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 682-688.	1.0	103
78	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet, The, 2017, 389, 1035-1042.	6.3	102
79	Optimal achieved blood pressure in acute intracerebral hemorrhage. Neurology, 2015, 84, 464-471.	1.5	101
80	Intracerebral hemorrhage location and outcome among INTERACT2 participants. Neurology, 2017, 88, 1408-1414.	1.5	101
81	Perindopril-Based Blood Pressureâ€“Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. Stroke, 2005, 36, 2164-2169.	1.0	100
82	Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention. JCI Insight, 2018, 3, .	2.3	100
83	Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy. Diabetes Care, 2012, 35, 2201-2206.	4.3	98
84	Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering. Journal of the American Society of Nephrology: JASN, 2007, 18, 2766-2772.	3.0	97
85	Erectile Dysfunction and Later Cardiovascular Disease in Men With Type 2 Diabetes. Journal of the American College of Cardiology, 2010, 56, 1908-1913.	1.2	94
86	Effects of clonidine on the baroreceptor-heart rate reflex and on single aortic baroreceptor fibre discharge. European Journal of Pharmacology, 1974, 28, 189-198.	1.7	93
87	Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. Journal of Hypertension, 2020, 38, 21-29.	0.3	93
88	Sex differences in treatment and outcome after stroke. Neurology, 2019, 93, e2170-e2180.	1.5	90
89	Glutamate in spinally projecting neurons of the rostral ventral medulla. Brain Research, 1991, 555, 326-331.	1.1	87
90	The pre-BÃ¶tzinger complex and phase-spanning neurons in the adult rat. Brain Research, 1998, 809, 204-213.	1.1	85

#	Article	IF	Citations
91	Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 2010, 31, 2888-2896.	1.0	85
92	Differential expression of catecholamine biosynthetic enzymes in the rat ventrolateral medulla. Journal of Comparative Neurology, 2001, 432, 20-34.	0.9	83
93	Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value in Health, 2016, 19, 36-41.	0.1	83
94	Rationale, Design, and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 Ã— 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowering in Patients with Acute Ischaemic Stroke Eligible for Thrombolysis Treatment. International Journal of Stroke, 2015, 10, 778-788.	2.9	82
95	The Relationship Between Alcohol Consumption and Vascular Complications and Mortality in Individuals With Type 2 Diabetes. Diabetes Care, 2014, 37, 1353-1359.	4.3	79
96	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1796-1803.	4.3	79
97	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer, 2016, 16, 488.	1.1	78
98	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.5	78
99	Plasma Neuropeptide Y Concentration Is Increased After Hemorrhage in Conscious Rats. Journal of Cardiovascular Pharmacology, 1987, 9, 541-545.	0.8	77
100	Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia, 2018, 61, 1581-1591.	2.9	76
101	Close appositions between Tyrosine hydroxylase immunoreactive boutons and respiratory neurons in the rat ventrolateral medulla. Journal of Comparative Neurology, 1994, 340, 1-10.	0.9	75
102	Lower Treatment Blood Pressure Is Associated With Greatest Reduction in Hematoma Growth After Acute Intracerebral Hemorrhage. Hypertension, 2010, 56, 852-858.	1.3	75
103	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet, The, 2021, 398, 1043-1052.	6.3	74
104	Examination of an eHealth literacy scale and a health literacy scale in a population with moderate to high cardiovascular risk: Rasch analyses. PLoS ONE, 2017, 12, e0175372.	1.1	74
105	Salt intake assessed by 24â€…h urinary sodium excretion in a random and opportunistic sample in Australia. BMJ Open, 2014, 4, e003720.	0.8	73
106	Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovascular Diabetology, 2016, 15, 129.	2.7	73
107	Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial. Blood Pressure, 2004, 13, 7-13.	0.7	72
108	Blood Pressure Variables and Cardiovascular Risk. Hypertension, 2009, 54, 399-404.	1.3	72

#	Article	IF	Citations
109	Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease. Circulation, 2005, 112, 110-116.	1.6	71
110	Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 95.	2.7	71
111	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. European Heart Journal, 2010, 31, 1854-1864.	1.0	70
112	Quantitative analysis of spinally projecting adrenaline-synthesising neurons of C1, C2 and C3 groups in rat medulla oblongata. Journal of the Autonomic Nervous System, 1990, 30, 209-220.	1.9	68
113	Medication reminder applications to improve adherence in coronary heart disease: a randomised clinical trial. Heart, 2019, 105, 323-329.	1.2	68
114	Substance P immunoreactive boutons form synapses with feline sympathetic preganglionic neurons. Journal of Comparative Neurology, 1992, 320, 121-135.	0.9	67
115	Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. Journal of Hypertension, 2000, 18, 327-334.	0.3	67
116	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	3.9	67
117	Altered c -fos in Rostral Medulla and Spinal Cord of Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 433-441.	1.3	66
118	The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 295-303.	4.3	65
119	Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1803-1810.	6.3	64
120	Participation of Central Serotonergic Neurons in the Control of the Circulation of the Unanesthetized Rabbit. Circulation Research, 1974, 35, 504-513.	2.0	62
121	Baseline Cognitive Function, Recurrent Stroke, and Risk of Dementia in Patients With Stroke. Stroke, 2013, 44, 1790-1795.	1.0	62
122	Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes. Diabetes Care, 2015, 38, 1891-1897.	4.3	62
123	Association of anthropometry and weight change with risk of dementia and its major subtypes: A metaâ€analysis consisting 2.8 million adults with 57 294 cases of dementia. Obesity Reviews, 2020, 21, e12989.	3.1	62
124	Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus. Hypertension, 2017, 70, 461-468.	1.3	61
125	The association of knowledge, attitudes and behaviours related to salt with 24-hour urinary sodium excretion. International Journal of Behavioral Nutrition and Physical Activity, 2014, 11, 47.	2.0	60
126	Release of substance P in the nucleus tractus solitarius measured by in vivo microdialysis: response to stimulation of the aortic depressor nerves in rabbit. Neuroscience Letters, 1988, 94, 131-137.	1.0	59

#	Article	IF	Citations
127	The 1999 WHOâ€“ISH Guidelines for the Management of Hypertension. Medical Journal of Australia, 1999, 171, 458-459.	0.8	59
128	Prior Events Predict Cerebrovascular and Coronary Outcomes in the PROGRESS Trial. Stroke, 2006, 37, 1497-1502.	1.0	59
129	Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2012, 1, e002832.	1.6	59
130	Significance of Cerebral Small-Vessel Disease in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 701-707.	1.0	59
131	Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500Â000 patients with Type 2 diabetes mellitus. European Heart Journal, 2019, 40, 2899-2906.	1.0	59
132	Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus. Hypertension, 2014, 63, 259-264.	1.3	55
133	Older age is a strong predictor for poor outcome in intracerebral haemorrhage: the INTERACT2 study. Age and Ageing, 2015, 44, 422-427.	0.7	55
134	The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. European Heart Journal, 2009, 30, 1385-1394.	1.0	54
135	Bï¿½tzinger neurons project towards bulbospinal neurons in the rostral ventrolateral medulla of the rat. , 1997, 388, 23-31.		51
136	Mannitol and Outcome in Intracerebral Hemorrhage. Stroke, 2015, 46, 2762-2767.	1.0	51
137	Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 2010, 28, 1141-1149.	0.3	50
138	Optimal size of cuff bladder for indirect measurement of arterial pressure in adults. Journal of Hypertension, 1989, 7, 607-613.	0.3	49
139	Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy. Stroke, 2012, 43, 1675-1677.	1.0	49
140	MEDication reminder APPs to improve medication adherence in Coronary Heart Disease (MedApp-CHD) Study: a randomised controlled trial protocol. BMJ Open, 2017, 7, e017540.	0.8	49
141	c-fos identifies GABA-synthesizing barosensitive neurons in caudal ventrolateral medulla. NeuroReport, 1997, 8, 3015-3021.	0.6	48
142	Significance of Hematoma Shape and Density in Intracerebral Hemorrhage. Stroke, 2016, 47, 1227-1232.	1.0	48
143	Efficacy and Safety of Quarter-Dose Blood Pressureâ€“Lowering Agents. Hypertension, 2017, 70, 85-93.	1.3	48
144	Does substance P coexist with adrenaline in neurones of the rostral ventrolateral medulla in the rat?. Neuroscience Letters, 1986, 71, 293-298.	1.0	47

#	Article	IF	Citations
145	Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. European Heart Journal, 2005, 26, 1910-1915.	1.0	47
146	A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. Journal of Hypertension, 2011, 29, 509-519.	0.3	47
147	Circulating bone morphogenetic protein-7 and transforming growth factor-Î²1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney International, 2013, 83, 278-284.	2.6	47
148	Determinants of Early Versus Delayed Neurological Deterioration in Intracerebral Hemorrhage. Stroke, 2019, 50, 1409-1414.	1.0	47
149	Degree and Timing of Intensive Blood Pressure Lowering on Hematoma Growth in Intracerebral Hemorrhage. Stroke, 2016, 47, 1651-1653.	1.0	46
150	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care, 2018, 41, 163-170.	4.3	46
151	EFFECTS OF TIMOLOL AND HYDROCHLOROTHIAZIDE ON BLOOD-PRESSURE AND PLASMA RENIN ACTIVITY Double-blind Factorial Trial. Lancet, The, 1976, 308, 328-331.	6.3	45
152	Renal sympathetic nerve responses to stimulation, inhibition and destruction of the ventrolateral medulla in the rabbit. Neuroscience Letters, 1985, 60, 51-55.	1.0	44
153	Magnitude of Blood Pressure Reduction and Clinical Outcomes in Acute Intracerebral Hemorrhage. Hypertension, 2015, 65, 1026-1032.	1.3	44
154	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia, 2019, 62, 1988-1997.	2.9	44
155	Revisiting lifestyle risk index assessment in a large Australian sample: Should sedentary behavior and sleep be included as additional risk factors?. Preventive Medicine, 2014, 60, 102-106.	1.6	43
156	Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. European Journal of Preventive Cardiology, 2016, 23, 1065-1076.	0.8	43
157	White blood cell count and clinical outcomes after intracerebral hemorrhage: The INTERACT2 trial. Journal of the Neurological Sciences, 2016, 361, 112-116.	0.3	43
158	Perindopril-based blood pressure lowering in individuals with cerebrovascular disease. Journal of Hypertension, 2004, 22, 653-659.	0.3	42
159	Earlier Blood Pressure-Lowering and Greater Attenuation of Hematoma Growth in Acute Intracerebral Hemorrhage. Stroke, 2012, 43, 2236-2238.	1.0	42
160	Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrology Dialysis Transplantation, 2012, 27, 1396-1402.	0.4	42
161	Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy. Stroke, 2017, 48, 1877-1883.	1.0	42
162	Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2018, 61, 780-789.	2.9	42

#	Article	IF	Citations
163	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Kidney International, 2021, 99, 926-939.	2.6	42
164	KYNURENIC ACID, AN ENDOGENOUS GLUTAMATE ANTAGONIST, IN SHR AND WKY RATS: POSSIBLE ROLE IN CENTRAL BLOOD PRESSURE REGULATION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 891-896.	0.9	41
165	Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Proâ€“B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease. Archives of Neurology, 2006, 63, 60.	4.9	41
166	PROGRESS: Prevention of Recurrent Stroke. Journal of Clinical Hypertension, 2011, 13, 693-702.	1.0	41
167	Significance of Intraventricular Hemorrhage in Acute Intracerebral Hemorrhage. Stroke, 2015, 46, 653-658.	1.0	40
168	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	40
169	Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension, 2019, 73, 84-91.	1.3	40
170	The Place of Combination Therapy in the Treatment of Hypertension in 1993. Clinical and Experimental Hypertension, 1993, 15, 1299-1313.	0.5	39
171	Prediction of Heart Failure by Amino Terminal-proâ€“B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease. Hypertension, 2005, 45, 69-74.	1.3	39
172	Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension. Journal of Hypertension, 2013, 31, 1043-1048.	0.3	38
173	Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care, 2017, 40, 1203-1209.	4.3	38
174	Ventral medulla stimulation increases blood pressure and spinal cord amino acid release. NeuroReport, 1992, 3, 55-58.	0.6	37
175	Effects of Perindopril-Based Blood Pressure Lowering and of Patient Characteristics on the Progression of Silent Brain Infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. Hypertension Research, 2004, 27, 147-156.	1.5	37
176	Effects of Blood Pressure Lowering on Major Vascular Events Among Patients With Isolated Diastolic Hypertension. Stroke, 2011, 42, 2339-2341.	1.0	37
177	Prognostic Significance of Hyponatremia in Acute Intracerebral Hemorrhage: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial Studies*. Critical Care Medicine, 2016, 44, 1388-1394.	0.4	37
178	Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean. Journal of Hypertension, 2019, 37, 16-23.	0.3	37
179	International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. Journal of Hypertension, 2003, 21, 651-63.	0.3	37
180	Lack of effect of fish oil supplementation on blood pressure in treated hypertensives. Journal of Hypertension, 1990, 8, 339-343.	0.3	35

#	Article	IF	Citations
181	Calbindin-immunoreactive neurons in the reticular formation of the rat brainstem: Catecholamine content and spinal projections. Journal of Comparative Neurology, 2000, 424, 547-562.	0.9	35
182	Dietary Salt Intake and Discretionary Salt Use in Two General Population Samples in Australia: 2011 and 2014. Nutrients, 2015, 7, 10501-10512.	1.7	35
183	Endothelial Gata5 transcription factor regulates blood pressure. Nature Communications, 2015, 6, 8835.	5.8	35
184	Intracellular recording from sympathetic preganglionic neurons in cat lumbar spinal cord. Brain Research, 1994, 656, 319-328.	1.1	34
185	Serotonin inputs to rabbit sympathetic preganglionic neurons projecting to the superior cervical ganglion or adrenal medulla. Journal of Comparative Neurology, 1995, 353, 427-438.	0.9	34
186	The Authors Reply. Kidney International, 2013, 84, 622.	2.6	34
187	Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. Journal of Hypertension, 2016, 34, 781-787.	0.3	34
188	Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke. Stroke, 2017, 48, 2605-2609.	1.0	34
189	Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial. PLoS ONE, 2013, 8, e55807.	1.1	34
190	Sympathetic preganglionic neurons in rabbit spinal cord that project to the stellate or the superior cervical ganglion. Brain Research, 1992, 577, 181-188.	1.1	33
191	Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke. JAMA Neurology, 2017, 74, 1328.	4.5	33
192	International Society of Hypertension (ISH). Journal of Hypertension, 2003, 21, 649-650.	0.3	32
193	Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension, 2010, 28, 395-400.	0.3	32
194	Impact of Blood Pressure Lowering on Cardiovascular Outcomes in Normal Weight, Overweight, and Obese Individuals. Hypertension, 2010, 55, 1193-1198.	1.3	32
195	Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World?. Diabetes Care, 2011, 34, 2491-2495.	4.3	32
196	Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial. Diabetes Care, 2014, 37, 2202-2210.	4.3	32
197	Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutrition and Diabetes, 2018, 8, 7.	1.5	32
198	Role of the Autonomic Nervous System in the Renal Vasoconstriction Response to Hemorrhage in the Rabbit. Circulation Research, 1967, 20, 676-685.	2.0	31

#	Article	IF	Citations
199	Effects of Vasopressin on Heart Rate in Conscious Rabbits. Journal of Cardiovascular Pharmacology, 1985, 7, 6-11.	0.8	31
200	Central serotonergic mechanisms in cardiovascular regulation. Cardiovascular Drugs and Therapy, 1990, 4, 27-32.	1.3	31
201	Projections from inspiratory neurons of the ventral respiratory group to the subretroficial nucleus of the cat. Brain Research, 1994, 633, 63-71.	1.1	31
202	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.4	31
203	Effects of a community-based salt reduction program in a regional Australian population. BMC Public Health, 2016, 16, 388.	1.2	31
204	Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage. American Journal of Kidney Diseases, 2016, 68, 94-102.	2.1	31
205	Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database. Stroke, 2018, 49, 1407-1411.	1.0	31
206	Blood Pressure Lowering for the Secondary Prevention of Myocardial Infarction and Stroke. Hypertension, 1997, 29, 537-538.	1.3	30
207	Use of the waistâ€toâ€height ratio to predict cardiovascular risk in patients with diabetes: <scp>R</scp>esults from the <scp>ADVANCEâ€ON</scp> study. Diabetes, Obesity and Metabolism, 2018, 20, 1903-1910.	2.2	29
208	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 862-872.	2.2	29
209	The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressureâ€"Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial. Diabetes Care, 2021, 44, 1622-1629.	4.3	29
210	Challenges for the Prevention of Primary and Secondary Stroke. The importance of lowering blood pressure and total cardiovascular risk. Blood Pressure, 2001, 10, 344-351.	0.7	28
211	The speed of ultraearly hematoma growth in acute intracerebral hemorrhage. Neurology, 2014, 83, 2232-2238.	1.5	28
212	Statistical Analysis Plan for Evaluating Low- vs. Standard-Dose Alteplase in the Enhanced Control of Hypertension and Thrombolysis Stroke Study (Enchanted). International Journal of Stroke, 2015, 10, 1313-1315.	2.9	28
213	PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease. Journal of Hypertension, 2017, 35, S24-S32.	0.3	28
214	Amino acid neurotransmitters in the central control of blood pressure and in experimental hypertension. Journal of Hypertension, 1992, 10, S27???38.	0.3	27
215	CENTRAL NEURONS AND NEUROTRANSMITTERS IN THE CONTROL OF BLOOD PRESSURE. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 819-829.	0.9	27
216	Synapses on axons of sympathetic preganglionic neurons in rat and rabbit thoracic spinal cord. Journal of Comparative Neurology, 1995, 354, 193-208.	0.9	26

#	Article	IF	Citations
217	Efficacy and Safety of an Oral Fixed Low-Dose Perindopril 2 mg/Indapamide 0.625 mg Combination: A Randomized, Double-Blind, Placebo-Controlled Study in Elderly Patients with Mild to Moderate Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1097-1110.	0.5	26
218	Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke, 2009, 40, 2111-2115.	1.0	26
219	Admission Heart Rate Predicts Poor Outcomes in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 1479-1485.	1.0	26
220	Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 2270-2277.	4.3	26
221	Relationship Between Plasma 8â€OHâ€Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. Journal of the American Heart Association, 2018, 7, .	1.6	26
222	Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialistsâ€™ Collaboration (BPLTTC). BMJ Open, 2019, 9, e028698.	0.8	26
223	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. Hypertension, 2019, 73, 1291-1299.	1.3	26
224	Poor Utility of Grading Scales in Acute Intracerebral Hemorrhage: Results from the Interact2 Trial. International Journal of Stroke, 2015, 10, 1101-1107.	2.9	25
225	Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 6-13.	0.9	25
226	Predicting the Effects of Blood Pressureâ€“Lowering Treatment on Major Cardiovascular Events for Individual Patients With Type 2 Diabetes Mellitus. Hypertension, 2015, 65, 115-121.	1.3	24
227	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia, 2021, 64, 2012-2025.	2.9	24
228	AMPA/kainate receptors mediate sympathetic chemoreceptor reflex in the rostral ventrolateral medulla. Brain Research, 1996, 726, 64-68.	1.1	23
229	Volhard Lecture Brain, blood pressure and stroke. Journal of Hypertension, 1998, 16, 1849-1858.	0.3	23
230	The lowering of blood pressure after stroke. Lancet, The, 2001, 358, 1994-1995.	6.3	23
231	Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE. Journal of Cardiovascular Pharmacology, 2010, 55, 340-347.	0.8	23
232	Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 498-503.	3.1	22
233	Dietary salt intake in the Australian population. Public Health Nutrition, 2017, 20, 1887-1894.	1.1	22
234	Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus. Journal of Alzheimer's Disease, 2020, 78, 3-12.	1.2	22

#	Article	IF	Citations
235	Antisense to Thyrotropin Releasing Hormone Receptor Reduces Arterial Blood Pressure in Spontaneously Hypertensive Rats. Circulation Research, 1995, 77, 679-683.	2.0	22
236	Effects of Sinoaortic Baroreceptor Denervation on Blood Pressure and PNMT Activity in Medulla Oblongata and Spinal Cord of Normotensive and Genetically Hypertensive Rats. Journal of Hypertension, 1985, 3, 81-87.	0.3	21
237	Effects of Intrathecal Administration of Methysergide, Phentolamine, and Pindolol on Pressor Responses to Electrical Stimulation of the Rostral Ventrolateral Medulla. Journal of Cardiovascular Pharmacology, 1988, 11, 456-460.	0.8	21
238	Subarachnoid Extension of Intracerebral Hemorrhage and 90-Day Outcomes in INTERACT2. Stroke, 2014, 45, 258-260.	1.0	21
239	Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease. Pharmacoeconomics, 2016, 34, 195-205.	1.7	21
240	Prognostic significance of delayed intraventricular haemorrhage in the INTERACT studies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 19-24.	0.9	21
241	Associations with health-related quality of life after intracerebral haemorrhage: pooled analysis of INTERACT studies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 70-75.	0.9	21
242	Thyrotropin-releasing hormone immunoreactive boutons form close appositions with medullary expiratory neurons in the rat. Brain Research, 1996, 715, 136-144.	1.1	20
243	Disparities between Prescribing of Secondary Prevention Therapies for Stroke and Coronary Artery Disease in General Practice. International Journal of Stroke, 2012, 7, 649-654.	2.9	20
244	The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia. Health Policy, 2015, 119, 620-627.	1.4	20
245	Effects of neuropeptide Y on the renal, mesenteric and hindlimb vascular beds of the conscious rabbit. Journal of the Autonomic Nervous System, 1989, 27, 139-146.	1.9	19
246	Felodipine, Metoprolol and Their Combination Compared with Placebo in Isolated Systolic Hypertension in the Elderly. Blood Pressure, 1994, 3, 82-89.	0.7	19
247	Blood Pressure Lowering for the Prevention of Cognitive Decline in Patients with Cerebrovascular Disease. Clinical and Experimental Hypertension, 1997, 19, 843-855.	0.5	19
248	Early Cognitive Impairment after Intracerebral Hemorrhage in the INTERACT1 Study. Cerebrovascular Diseases, 2017, 44, 320-324.	0.8	19
249	Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke. Neurology: Clinical Practice, 2017, 7, 324-332.	0.8	19
250	Blood pressure variability and outcome in acute ischemic and hemorrhagic stroke: a post hoc analysis of the HeadPoST study. Journal of Human Hypertension, 2019, 33, 411-418.	1.0	19
251	Infratentorial Intracerebral Hemorrhage. Stroke, 2019, 50, 1257-1259.	1.0	19
252	Implementation of Guidelines for Management of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 647-657.	0.5	18

#	Article	IF	Citations
253	ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension, 2006, 24, S22-S28.	0.3	18
254	Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 98, 83-90.	1.1	18
255	Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1284-1285.	0.9	18
256	Yogaâ€™s effect on inflammatory biomarkers and metabolic risk factors in a high risk population â€“ a controlled trial in primary care. BMC Cardiovascular Disorders, 2015, 15, 91.	0.7	18
257	Assessment of cardiac autonomic excitability in renal hypertensive rabbits using clonidine-induced resetting of the baroreceptor-heart rate reflex. European Journal of Pharmacology, 1975, 33, 353-362.	1.7	17
258	Differences in the Central Hypotensive Actions of Î±-Methyldopa and Clonidine in the Spontaneously Hypertensive Rat. Journal of Cardiovascular Pharmacology, 1990, 15, 118-123.	0.8	17
259	Mono- and Combination Therapy with Felodipine or Enalapril in Elderly Patients with Systolic Hypertension. Blood Pressure, 1994, 3, 90-96.	0.7	17
260	Activation of spinal opioid receptors contributes to hypotension after hemorrhage in conscious rats. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1552-H1558.	1.5	17
261	The Importance of Drug Combinations for Effective Control of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 875-884.	0.5	17
262	Blood-Pressure Lowering in Acute Intracerebral Hemorrhage. New England Journal of Medicine, 2013, 369, 1273-1275.	13.9	17
263	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 152-162.	1.8	17
264	Relative Importance of Sympathetic Nerves and of Circulating Adrenaline and Vasopressin in Mediating Hypertension After Lesions of the Caudal Ventrolateral Medulla in the Rat. Journal of Hypertension, 1986, 4, 273-281.	0.3	16
265	The use of microinjected colloidal gold and immunocytochemistry to localise pressor sites in the rostral medulla oblongata of the rat. Neuroscience Letters, 1987, 77, 125-130.	1.0	16
266	Is a Blood Pressure Target of <130/80 mm Hg Still Appropriate for High-Risk Patients?. Circulation, 2011, 124, 1700-1702.	1.6	16
267	Reduced blood pressure after smooth muscle EFNB2 deletion and the potential association of EFNB2 mutation with human hypertension risk. European Journal of Human Genetics, 2016, 24, 1817-1825.	1.4	16
268	Using administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from Australia. Health Policy, 2017, 121, 426-433.	1.4	16
269	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia, 2020, 63, 1637-1647.	2.9	16
270	Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke. Neurology, 2021, 96, e1512-e1526.	1.5	16

#	Article	IF	Citations
271	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Medicine, 2021, 18, e1003599.	3.9	16
272	Substance P-immunoreactive boutons closely appose inspiratory protruder hypoglossal motoneurons in the cat. Brain Research, 1999, 834, 155-159.	1.1	15
273	Delta pioid receptor immunoreactive boutons appose bulbospinal CI neurons in the rat. NeuroReport, 2000, 11, 887-891.	0.6	15
274	Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study. PLoS ONE, 2016, 11, e0149040.	1.1	15
275	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. Diabetes Care, 2020, 43, 1293-1299.	4.3	15
276	THERE ARE FEW CATECHOLAMINE- OR NEUROPEPTIDE Y-CONTAINING SYNAPSES IN THE INTERMEDIOLATERAL CELL COLUMN OF RAT THORACIC SPINAL CORD. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 111-115.	0.9	14
277	AXONAL PROJECTIONS FROM RESPIRATORY CENTRES TOWARDS THE ROSTRAL VENTROLATERAL MEDULLA IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 335-338.	0.9	14
278	Respiratory Inputs to Central Cardiovascular Neurons. Annals of the New York Academy of Sciences, 1996, 783, 64-70.	1.8	14
279	Reliable and unbiased assessment of the effects of calcium antagonists. Journal of Hypertension, 1997, 15, 1201-1204.	0.3	14
280	Identification of Posterior Cricoarytenoid Motoneurons in the Rat. Annals of Otology, Rhinology and Laryngology, 1999, 108, 1033-1041.	0.6	14
281	Trials on blood pressureâ€“lowering and secondary stroke prevention. American Journal of Cardiology, 2003, 91, 3-8.	0.7	14
282	Diuretics: A modern day treatment option? (Review Article). Nephrology, 2006, 11, 419-427.	0.7	14
283	Comparability of Patient-reported Health Status. Medical Care, 2011, 49, 962-970.	1.1	14
284	Early blood pressure lowering in patients with intracerebral haemorrhage and prior use of antithrombotic agents: pooled analysis of the INTERACT studies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1330-1335.	0.9	14
285	Cumulative in-trial and post-trial effects of blood pressure and lipid lowering. Journal of Hypertension, 2017, 35, 905-913.	0.3	14
286	C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register. Diabetes Research and Clinical Practice, 2019, 150, 174-183.	1.1	14
287	Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome. Stroke, 2020, 51, 2411-2417.	1.0	14
288	Ultra-low-dose quadruple combination blood pressureâ€“lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. American Heart Journal, 2021, 231, 56-67.	1.2	14

#	Article	IF	Citations
289	Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. Stroke, 2022, 53, 779-787.	1.0	14
290	J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: A pooled analysis of INTERACT2 and ATACH-II individual participant data. International Journal of Stroke, 2022, , 174749302110640.	2.9	14
291	Effect of Indomethacin on Blood Pressure Control during Treatment with Nitrendipine. Blood Pressure, 1995, 4, 307-312.	0.7	13
292	Respiratory Activity of the Rat Posterior Cricoarytenoid Muscle. Annals of Otology, Rhinology and Laryngology, 1997, 106, 897-901.	0.6	13
293	Phosphate-activated glutaminase immunoreactivity in brainstem respiratory neurons. Journal of the Autonomic Nervous System, 1997, 63, 85-90.	1.9	13
294	Enhancing risk stratification in hypertensive subjects: how far should we go in routine screening for target organ damage?. Journal of Hypertension, 2002, 20, 1255-1257.	0.3	13
295	Blood pressure in acute stroke: in search of evidence. Journal of Hypertension, 2005, 23, 277-278.	0.3	13
296	Ambient Temperature and Volume of Perihematomal Edema in Acute Intracerebral Haemorrhage: The INTERACT1 Study. International Journal of Stroke, 2015, 10, 25-27.	2.9	13
297	Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review. Stroke and Vascular Neurology, 2018, 3, 28-33.	1.5	13
298	NIHSS cut point for predicting outcome in supra- vs infratentorial acute ischemic stroke. Neurology, 2018, 91, e1695-e1701.	1.5	13
299	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. Stroke, 2019, 50, 2187-2196.	1.0	13
300	Changes in plasma lipids predict pravastatin efficacy in secondary prevention. JCI Insight, 2019, 4, .	2.3	13
301	New Blood Pressure Guidelines Pose Difficult Choices for Australian Physicians. Circulation Research, 2019, 124, 975-977.	2.0	13
302	Sex differences in treatment, radiological features and outcome after intracerebral haemorrhage: Pooled analysis of Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage trials 1 and 2. European Stroke Journal, 2020, 5, 345-350.	2.7	13
303	Comparative effects of intensive-blood pressure versus standard-blood pressure-lowering treatment in patients with severe ischemic stroke in the ENCHANTED trial. Journal of Hypertension, 2021, 39, 280-285.	0.3	13
304	Do pressor neurons in the ventrolateral medulla release amines and neuropeptides?. Canadian Journal of Physiology and Pharmacology, 1987, 65, 1598-1604.	0.7	12
305	Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. Journal of Hypertension, 1990, 8, 1015-1019.	0.3	12
306	KAINIC ACID INJECTION IN NTS EVOKES HYPERTENSION AND C-FOS EXPRESSION IN SPINAL CORD. NeuroReport, 1992, 3, 437-440.	0.6	12

#	Article	IF	Citations
307	Neurokinin-1 receptors and spinal cord control of blood pressure in spontaneously hypertensive rats. Brain Research, 1999, 815, 116-120.	1.1	12
308	All hats off to ALLHAT. Journal of Hypertension, 2003, 21, 225-228.	0.3	12
309	Costâ€effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trialâ€based analysis. Medical Journal of Australia, 2010, 193, 320-324.	0.8	12
310	Higher mortality in patients with right hemispheric intracerebral haemorrhage: INTERACT1 and 2. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1319-1323.	0.9	12
311	Prophylactic heparin in acute intracerebral hemorrhage: a propensity score-matched analysis of the INTERACT2 study. International Journal of Stroke, 2016, 11, 549-556.	2.9	12
312	Comparison of ABC Methods with Computerized Estimates of Intracerebral Hemorrhage Volume: The INTERACT2 Study. Cerebrovascular Diseases Extra, 2020, 9, 148-154.	0.5	12
313	Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1775-1785.	2.2	12
314	Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study. Journal of Stroke, 2018, 20, 131-139.	1.4	12
315	COMPLEMENTARY CHANGES IN PLASMA ATRIAL NATRIURETIC PEPTIDE AND ANTIDIURETIC HORMONE CONCENTRATIONS IN RESPONSE TO VOLUME EXPANSION AND HAEMORRHAGE: STUDIES IN CONSCIOUS NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 283-289.	0.9	11
316	BLOOD PRESSURE LOWERING IN PATIENTS WITH CEREBROVASCULAR DISEASE: RESULTS OF THE PROGRESS (PERINDOPRIL PROTECTION AGAINST RECURRENT STROKE STUDY) PILOT PHASE. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 444-446.	0.9	11
317	Intracellular Recording from Posterior Cricoarytenoid Motoneurons in the Rat. Annals of Otology, Rhinology and Laryngology, 1999, 108, 1120-1125.	0.6	11
318	Spinal GABA_A receptors do not mediate the sympathetic baroreceptor reflex in the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R320-R331.	0.9	11
319	Early Blood Pressure Lowering Does Not Reduce Growth of Intraventricular Hemorrhage following Acute Intracerebral Hemorrhage: Results of the INTERACT Studies. Cerebrovascular Diseases Extra, 2017, 6, 71-75.	0.5	11
320	History of lower-limb complications and risk of cancer death in people with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 3.	2.7	11
321	IMPORTANCE OF CENTRAL SEROTONIN NEURONS IN THE HYPOTENSIVE ACTION OF METHYLDOPA IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1984, 11, 37-44.	0.9	10
322	The PROGRESS trial three years later: time for more action, less distraction. BMJ: British Medical Journal, 2004, 329, 970-971.	2.4	10
323	Protocol for the implementation and evaluation of a community-based intervention seeking to reduce dietary salt intake in Lithgow, Australia. BMC Public Health, 2014, 14, 357.	1.2	10
324	Evidence from single nucleotide polymorphism analyses of ADVANCE study demonstrates EFNB3 as a hypertension risk gene. Scientific Reports, 2017, 7, 44114.	1.6	10

#	Article	IF	Citations
325	EPHA4 regulates vascular smooth muscle cell contractility and is a sex-specific hypertension risk gene in individuals with type 2 diabetes. Journal of Hypertension, 2019, 37, 775-789.	0.3	10
326	Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy. International Journal of Stroke, 2019, 14, 555-558.	2.9	10
327	Sympathetic preganglionic neurons projecting to the adrenal medulla and aorticorenal ganglion in the rabbit. Brain Research, 1992, 586, 125-129.	1.1	9
328	The National Consensus Conferenceâ€"Not Always What It Seems. Blood Pressure, 1994, 3, 4-6.	0.7	9
329	Role of spinal GABA receptors in depressor responses to chemical stimulation of the A5 area in normal and hypertensive rats. Journal of the Autonomic Nervous System, 1997, 66, 53-61.	1.9	9
330	Rapid Blood-Pressure Lowering in Patients With Acute Intracerebral Hemorrhage. Survey of Anesthesiology, 2014, 58, 24-26.	0.1	9
331	Practice Patterns for Neurosurgical Utilization and Outcome in Acute Intracerebral Hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials 1 and 2 Studies. Neurosurgery, 2017, 81, 980-985.	0.6	9
332	Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial. Journal of the Neurological Sciences, 2018, 387, 1-5.	0.3	9
333	Response of 1,5â€anhydroglucitol level to intensive glucoseâ€and bloodâ€pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial. Diabetes, Obesity and Metabolism, 2019, 21, 2017-2023.	2.2	9
334	Who will benefit more from low-dose alteplase in acute ischemic stroke?. International Journal of Stroke, 2020, 15, 39-45.	2.9	9
335	Sexâ€specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: The <scp>ADVANCEâ€ON</scp> study. Diabetes, Obesity and Metabolism, 2020, 22, 1818-1826.	2.2	9
336	Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm. International Journal of Stroke, 2021, 16, 222-228.	2.9	9
337	Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes. Diabetes, 2021, 70, 255-261.	0.3	9
338	Associations of an Abnormal Physiological Score With Outcomes in Acute Intracerebral Hemorrhage. Stroke, 2021, 52, 722-725.	1.0	9
339	Mild hypertension: A summary of the 1993 World Health Organization/International Society of Hypertension (WHO/ISH) guidelines for the management of mild hypertension Memorandum from a WHO/ISH meetingâ€. Journal of Internal Medicine, 1994, 235, 21-29.	2.7	8
340	Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. Journal of Hypertension, 1997, 15, 1503-1510.	0.3	8
341	Progress In Reducing The Burden Of Stroke*. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1091-1095.	0.9	8
342	Comparison of Various Blood Pressure Lowering Treatments on the Primary Prevention of Cardiovascular Outcomes in Recent Randomised Clinical Trials. Clinical and Experimental Hypertension, 2004, 26, 709-719.	0.5	8

#	Article	IF	Citations
343	Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. Journal of Hypertension, 2007, 25, 699-705.	0.3	8
344	How fair is Medicare? The incomeâ€related distribution of Medicare benefits with special focus on chronic care items. Medical Journal of Australia, 2012, 197, 625-630.	0.8	8
345	Statistical Analysis Plan for the Second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). International Journal of Stroke, 2013, 8, 327-328.	2.9	8
346	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 2016, 59, 2603-2612.	2.9	8
347	Risk factors and consequences of decreased kidney function in nursing home residents: A longitudinal study. Geriatrics and Gerontology International, 2017, 17, 791-797.	0.7	8
348	Intensive versus guidelineâ€recommended blood pressure reduction in acute lacunar stroke with intravenous thrombolysis therapy: The ENCHANTED trial. European Journal of Neurology, 2021, 28, 783-793.	1.7	8
349	Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes. Canadian Journal of Diabetes, 2021, 45, 129-136.	0.4	8
350	Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. Kidney International Reports, 2021, 6, 284-295.	0.4	8
351	Altered responsiveness of medullary depressor neurones to L-glutamate and D-serine in SHR rats. NeuroReport, 1996, 7, 1409-1412.	0.6	7
352	The management of blood pressure in acute stroke. Lancet Neurology, The, 2003, 2, 593.	4.9	7
353	ADVANCE: Lessons from the runâ€in phase of a large study in type 2 diabetes. Blood Pressure, 2006, 15, 340-346.	0.7	7
354	Intensive glucoseâ€lowering and the risk of vascular events and premature death in patients with decreased kidney function: The ADVANCE trial. Diabetes, Obesity and Metabolism, 2020, 22, 452-457.	2.2	7
355	Thrombolysis Outcomes in Acute Ischemic Stroke by Fluid-Attenuated Inversion Recovery Hyperintense Arteries. Stroke, 2020, 51, 2240-2243.	1.0	7
356	The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65â€‰years: Results from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1292-1300.	2.2	7
357	The treatment of hypertension. British Journal of Clinical Pharmacology, 1996, 42, 29-35.	1.1	6
358	TACHYCARDIA AFTER GLUTAMATE INJECTION IN RAT SPINAL CORD IS NOT BLOCKED BY KYNURENATE OR MIMICKED BY METABOTROPIC AGONISTS. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 813-818.	0.9	6
359	Central control mechanisms in hypertension. Australian and New Zealand Journal of Medicine, 1997, 27, 474-478.	0.5	6
360	Blood Pressure Lowering In Diabetes: A Brief Review Of The Current Evidence And Description Of A New Trial. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1108-1111.	0.9	6

#	Article	IF	Citations
361	Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 413-418.	3.1	6
362	ADVANCES IN REDUCING THE BURDEN OF VASCULAR DISEASE IN TYPE 2 DIABETES. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 434-437.	0.9	6
363	An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event. European Journal of Health Economics, 2009, 10, 111-119.	1.4	6
364	Measuring the Progressivity of the Pharmaceutical Benefits Scheme. Australian Economic Review, 2015, 48, 122-132.	0.4	6
365	Circadian variation in clinical features and outcome of intracerebral hemorrhage: The INTERACT studies. Chronobiology International, 2016, 33, 1182-1187.	0.9	6
366	Strategies to meet the need for long-term data. Journal of Hypertension, 2016, 34, 1473-1479.	0.3	6
367	Determinants of the high admission blood pressure in mild-to-moderate acute intracerebral hemorrhage. Journal of Hypertension, 2019, 37, 1463-1466.	0.3	6
368	Smoking influences outcome in patients who had thrombolysed ischaemic stroke: the ENCHANTED study. Stroke and Vascular Neurology, 2021, 6, e000493.	1.5	6
369	Opioid innervation of the caudal ventrolateral medulla is not critical for the expression of the aortic depressor nerve response in the rabbit. Journal of the Autonomic Nervous System, 1991, 32, 37-46.	1.9	5
370	Lowering blood pressure in 2003. Medical Journal of Australia, 2003, 179, 306-312.	0.8	5
371	New insights from ADVANCE. Journal of Hypertension, 2007, 25, S23-S30.	0.3	5
372	Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. Journal of Hypertension, 2008, 26, S21-S27.	0.3	5
373	Cost-effective reduction in stroke. Journal of Hypertension, 2012, 30, 1706-1707.	0.3	5
374	The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality?. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1628-1633.	1.1	5
375	Ambient Temperature and Severity of Intracerebral Haemorrhage: The INTERACT1 Study. Neuroepidemiology, 2014, 42, 169-173.	1.1	5
376	Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial. Stroke and Vascular Neurology, 2017, 2, 53-58.	1.5	5
377	Withdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 study. Age and Ageing, 2017, 46, 329-332.	0.7	5
378	Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and <scp>allâ€cause</scp> mortality in individuals with type 2 diabetes in the <scp>ADVANCE</scp> trial. Journal of Diabetes, 2020, 12, 929-941.	0.8	5

#	Article	IF	Citations
379	Disparities between Asian and Non-Asian Thrombolyzed Acute Ischemic Stroke Patients in the Enhanced Control of Hypertension and Thrombolysis Stroke Trial. Cerebrovascular Diseases, 2021, 50, 560-566.	0.8	5
380	Etude ADVANCE : objectifs, protocole et ??tat actuel. Drugs, 2003, 63, 39-44.	4.9	5
381	Management of hypertension: evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration and from major clinical trials. , 2009, 119, 373-80.		5
382	Cardiovascular effects of intracisternal 6-hydroxydopamine and of subsequent lesions of the ventrolateral medulla coinciding with the A1 group of noradrenaline cells in the rabbit. Journal of the Autonomic Nervous System, 1985, 12, 117-130.	1.9	4
383	A LACK OF POTENCY FOR THE ?-OPIOID ANTAGONIST NALTRINDOLE AFTER MICROINJECTION INTO THE ROSTRAL VENTROLATERAL MEDULLA OF RABBITS. Clinical and Experimental Pharmacology and Physiology, 1990, 17, 527-530.	0.9	4
384	Are the Ventrally Projecting Dendrites of Respiratory Neurons a Neuroanatomical Basis for the Chemosensitivity of the Ventral Medulla Oblongata?. Sleep, 1993, , .	0.6	4
385	Glycemic control and outcomes in people with diabetes and CKD. Nature Reviews Nephrology, 2012, 8, 133-134.	4.1	4
386	Side effects and tolerability of combination blood pressure lowering according to blood pressure levels. Journal of Hypertension, 2017, 35, 1318-1325.	0.3	4
387	Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy, 2017, 121, 1233-1239.	1.4	4
388	Salt intake and dietary sources of salt on weekdays and weekend days in Australian adults. Public Health Nutrition, 2018, 21, 2174-2182.	1.1	4
389	Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Cerebrovascular Diseases, 2018, 45, 213-220.	0.8	4
390	Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke. Stroke, 2020, 51, 588-593.	1.0	4
391	Impact of Model Choice When Studying the Relationship Between Blood Pressure Variability and Risk of Stroke Recurrence. Hypertension, 2021, 78, 1520-1526.	1.3	4
392	Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2008, 26, S21-7.	0.1	4
393	The Blood Pressure Lowering Treatment Trialistsâ€™ Collaboration. Journal of Hypertension, 2022, Publish Ahead of Print, .	0.3	4
394	Is Blood Pressure Lowering in the Very Elderly With Previous Stroke Associated With a Higher Risk of Adverse Events?. Journal of the American Heart Association, 2021, 10, e022240.	1.6	4
395	The HOT Study: Design and Cost of Major Blood Pressure Trials. Blood Pressure, 1994, 3, 276-278.	0.7	3
396	The ABCD of anti-hypertensive therapy?. Journal of Hypertension, 2002, 20, 615-616.	0.3	3

#	Article	IF	Citations
397	Secondary prevention of stroke by blood pressure-lowering treatment. Current Hypertension Reports, 2006, 8, 317-323.	1.5	3
398	Hypertension Guidelines: Timely New Initiatives from East Asia. Pulse, 2015, 3, 1-3.	0.9	3
399	Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study. Cerebrovascular Diseases, 2019, 48, 207-216.	0.8	3
400	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1420-1425.	2.2	3
401	The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges. Current Drug Safety, 2013, 8, 371-378.	0.3	3
402	Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress. International Journal of Stroke, 2022, 17, 1156-1162.	2.9	3
403	Correlation between fall in blood pressure and in vivo amine release after Î±-methylDOPA. European Journal of Pharmacology, 1989, 164, 531-538.	1.7	2
404	Blood pressure and stroke: a continuing debate. Journal of Hypertension, 2006, 24, 1249-1251.	0.3	2
405	Issues in the development of new combinations of blood pressure lowering drugs. Journal of Hypertension, 2010, 28, 2494-2496.	0.3	2
406	Multiple risk factor interventions and inflammatory biomarkers in high risk individuals with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 95, 386-388.	1.1	2
407	Can blood pressure-lowering therapy reduce the risk of cognitive decline in the elderly?. Journal of Hypertension, 2015, 33, 2029-2031.	0.3	2
408	Guidelines under fire again!*. Journal of Hypertension, 2017, 35, 1567-1568.	0.3	2
409	Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm. Cerebrovascular Diseases, 2020, 49, 427-436.	0.8	2
410	Sex differences in predictors for cognitive decline and dementia in people with stroke or transient ischemic attack in the PROGRESS trial. International Journal of Stroke, 2021, , 174749302110592.	2.9	2
411	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. International Journal of Cardiology, 2022, 358, 103-109.	0.8	2
412	EFFERENT MECHANISMS RESPONSIBLE FOR THE BRADYCARDIA PRODUCED BY LESIONS COINCIDING WITH THE A1 GROUP OF CENTRAL CATECHOLAMINE NEURONS IN THE CONSCIOUS RABBIT. Clinical and Experimental Pharmacology and Physiology, 1984, 11, 143-154.	0.9	1
413	The ADVANCE trial â€“ Authors' reply. Lancet, The, 2008, 371, 26.	6.3	1
414	Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. Expert Review of Endocrinology and Metabolism, 2009, 4, 111-118.	1.2	1

#	Article	IF	Citations
415	Blood pressure lowering in acute strokeâ€"scant joy from SCAST. Nature Reviews Cardiology, 2011, 8, 366-368.	6.1	1
416	Response to Comment on Hillis et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295â€"303. Diabetes Care, 2014, 37, e154-e154.	4.3	1
417	Are the effects of telmisartan more marked in hypertensive patients?. Journal of Hypertension, 2014, 32, 1201-1202.	0.3	1
418	How far to lower blood pressure in the long term, after a stroke?. Journal of Hypertension, 2014, 32, 746-748.	0.3	1
419	Blood pressure control after a stroke. Journal of Hypertension, 2015, 33, 2022-2024.	0.3	1
420	Positive impact of the participation in the ENCHANTED trial in reducing Door-to-Needle Time. Scientific Reports, 2017, 7, 14168.	1.6	1
421	Guidelines Under Fire Again!. Hypertension, 2017, 70, 238-239.	1.3	1
422	The National Institute for Health Research Hyperacute Stroke Research Centres and the ENCHANTED trial: the impact of enhanced research infrastructure on trial metrics and patient outcomes. Health Research Policy and Systems, 2019, 17, 19.	1.1	1
423	Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Programme registry. International Journal of Stroke, 2019, 14, 678-685.	2.9	1
424	Observational analyses from ADVANCE and ADVANCEâ€ON. Diabetes, Obesity and Metabolism, 2020, 22, 19-32.	2.2	1
425	Regional Differences in Early BP Management After Acute Ischemic Stroke in the ENCHANTED International Randomized Controlled Trials. Frontiers in Neurology, 2021, 12, 687862.	1.1	1
426	Women in Medicine. Medical Journal of Australia, 1992, 157, 726-727.	0.8	1
427	Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes. Journal of Human Hypertension, 2022, , .	1.0	1
428	Connecting the dots: ongoing ace inhibition trials and what they can tell us Tuesday, may 16, broadway ballroom north, 5:30 pm to 7:30 pm. ace inhibitors: more than just bp reduction. American Journal of Hypertension, 2000, 13, S325.	1.0	0
429	Diabetes and Vascular Disease: A New International Trial. Asian Cardiovascular and Thoracic Annals, 2003, 11, 180-184.	0.2	0
430	New strategies for hypertension control. American Journal of Cardiovascular Drugs, 2004, 4, 37-42.	1.0	0
431	Introduction. Journal of Hypertension, 2007, 25, S1-S2.	0.3	0
432	INTRODUCTION. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 361-361.	0.9	0

#	Article	IF	Citations
433	Antalya statement of the International Society of Hypertension on the prevention of blood pressure-related diseases. Journal of Hypertension, 2008, 26, 2255-2258.	0.3	0
434	ADVANCE: Blood Pressure Lowering in Diabetes. Journal of Clinical Hypertension, 2009, 11, 108-108.	1.0	0
435	Response to Letter by Kerr and Nasco. Stroke, 2009, 40, .	1.0	0
436	Event Rates in Trials of Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 303, 732.	3.8	0
437	Cognitive Function and Dementia in Hypertension: Epidemiologic and Therapeutic Aspects. , 2012, , 399-412.		0
438	Making Good Use of Diastolic and Systolic Blood Pressures in the Management of Hypertension. Hypertension, 2012, 60, 1110-1111.	1.3	0
439	Current issues with dual inhibition of the reninâ€“angiotensin system. Journal of Hypertension, 2013, 31, 261-262.	0.3	0
440	Blood pressure and cerebral ischemia. Neurology, 2014, 82, 1018-1019.	1.5	0
441	The development and feasibility of a composite score of echocardiographic indices that may stratify outcome in patients with diabetes mellitus. International Journal of Cardiology, 2015, 182, 244-249.	0.8	0
442	Microvascular outcomes in type 2 diabetes â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 580.	5.5	0
443	Response to Comment on Ohkuma et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017;40:1203â€“1209. Diabetes Care, 2018, 41, e39-e39.	4.3	0
444	Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target. International Journal of Stroke, 2021, , 174749302110254.	2.9	0
445	PROGRESS in Blood Pressure Control for the Prevention of Secondary Stroke. Cerebrovascular Diseases, 2021, 50, 1-5.	0.8	0
446	Cerebrovascular Disease in Hypertension. , 2007, , 392-405.		0
447	Variables tensionnelles etÂrisque cardiovasculaire chezÂlesÂdiabÃ©tiques deÂtype 2Ådans l'Ã©tude ADVANCE*. Sang Thrombose Vaisseaux, 2010, 22, 264-270.	0.1	0
448	Cerebrovascular Disease in Hypertension. , 2013, , 303-312.		0
449	Afferent Inputs to Ventrolateral Medulla. , 1991, , 3-13.		0
450	Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial. Diabetes Research and Clinical Practice, 2021, 182, 109148.	1.1	0

#	Article	IF	Citations
451	Introduction: advances in the prevention of cardiovascular disease in patients with diabetes. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2008, 26, S1-2.	0.1	0